XOMA Corporation, a development stage biotechnology company, discovers, develops, and commercializes antibody-based therapeutics in the United States, Europe, and the Asia Pacific. The company's product candidates include XOMA 358, a human negative allosteric modulating insulin receptor antibody is in phase 2 proof-of-concept study for treating congenital hyperinsulinism and post-meal hypoglycemia in post-bariatric surgery patients; XOMA 129, a potent fragment of a monoclonal antibody is under preclinical testing to treat patients with acute severe hypoglycemia; XOMA 213, a allosteric inhibitor for use in treating prolactinoma and anti-psychotic-induced hyperprolactinemia. It also licenses antibody discovery, optimization, and development technologies, including Antibody Discovery Advanced Platform Technologies, ModulX, and OptimX. The company has research and development collaboration and licensing agreements with Novartis AG; Novo Nordisk A/S; Takeda Pharmaceutical Company Limited; and Pfizer Inc. XOMA Corporation was founded in 1981 and is headquartered in Berkeley, California.
http://www.priceseries.com/trade/XOMA-XOMA-Corporation-stock-gains-204-percent-a-Trade-Record-by-priceSeries-2017081720171020.html
Subscribe by Email
Follow Updates Articles from This Blog via Email
No Comments